IDEXX Laboratories stock trades near record levels as diagnostics growth supports valuation
Published on 07/22/2026 at 05:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
IDEXX Laboratories (ISIN US45168D1046) stock has been trading near its record range on Nasdaq in recent months, supported by double digit revenue growth in its companion animal diagnostics segment and resilient profitability across the group.
Revenue up double digits in 2024
According to the companys most recent annual report for fiscal 2024, available via the Investor Relations section of IDEXX Laboratories, total revenue reached approximately $4.0 billion in 2024, up around 10% from about $3.6 billion in 2023 as the company continued to expand its global diagnostics footprint.
Within that total, companion animal group revenue accounted for the majority of sales and grew at a faster pace than the consolidated figure. The annual report indicates that companion animal revenue in 2024 was roughly $3.3 billion, compared with about $3.0 billion in 2023, implying growth of around 10% year on year as veterinary practices increased testing volumes and adopted more advanced diagnostic panels.
Operating margin and earnings develop
The same fiscal 2024 filing shows that operating income rose in line with revenue, with operating profit estimated at around $1.1 billion in 2024 versus approximately $1.0 billion in 2023. That translates into an operating margin in the high twenties percent, underlining the companys ability to convert diagnostics volume growth into earnings despite ongoing investment in R&D and commercial capabilities.
Net income attributable to IDEXX Laboratories in fiscal 2024 was reported at roughly $830 million, compared with about $760 million in 2023, reflecting earnings growth of more than 9% alongside the revenue increase. Diluted earnings per share in 2024 were indicated at approximately $10.00, up from around $9.00 in the prior year, as the company benefited both from higher operating profits and a modest reduction in share count through repurchases.
Companion diagnostics product focus
IDEXX Laboratories generates a significant share of its revenue from companion animal diagnostics platforms installed in veterinary practices worldwide, supported by recurring sales of consumables and test kits. The companys flagship analyzers and point of care testing systems are positioned to capture growing demand for comprehensive diagnostics as pet owners increasingly seek advanced care and veterinarians integrate diagnostics into routine workflows. In recent reporting periods, management has highlighted that installed base growth of analyzers and associated utilization trends are central drivers of revenue expansion in the companion animal segment.
Stock and valuation context
IDEXX Laboratories stock is traded on Nasdaq under the ticker IDXX and is a component of major US equity benchmarks for large and mid cap healthcare and diagnostics companies. Market data from leading financial portals as of mid 2026 show that the companys market capitalization is in the range of $45 billion to $50 billion, reflecting investor expectations for continued revenue growth in the high single to low double digit range and sustained strong margins.
For investors, the interaction between diagnostics volume growth, margin stability, and valuation multiples remains central. With revenue having increased from approximately $3.6 billion in 2023 to around $4.0 billion in 2024 and operating margins remaining in the high twenties percent, IDEXX Laboratories is positioned as a premium valued diagnostics and veterinary technology name. The degree to which the company can continue expanding its installed analyzer base, grow consumables throughput, and develop new test panels will help determine whether earnings can keep pace with the ambitious expectations implied by its current market capitalization.
More on IDEXX Laboratories
Further details on IDEXX Laboratories financials and diagnostics strategy are available via the companys Investor Relations materials and additional market coverage.
Diagnostic analyzers support growth
IDEXX Laboratories key diagnostic analyzers installed in veterinary practices worldwide form the backbone of its recurring revenue model. These systems are linked to proprietary consumables and reagents that generate ongoing income as clinics run hematology tests, chemistry panels, infectious disease assays, and specialty diagnostics. Company disclosures for fiscal 2024 suggest that the installed base of analyzers continued to rise year on year, contributing to higher consumables throughput and underpinning the approximately 10% companion animal revenue growth from about $3.0 billion in 2023 to roughly $3.3 billion in 2024.
Stock and market data snapshot
Market quotes from prominent Nasdaq data providers indicate that IDEXX Laboratories stock has traded in a broad range over the last twelve months, with a 52 week span that reflects substantial investor interest and valuation sensitivity to diagnostics growth rates. As of mid 2026, the share price has been near the upper end of this 52 week range, consistent with the companys solid fiscal 2024 performance and expectations for continued growth in companion animal diagnostics and other business lines.
IDEXX Laboratories key data
- Company: IDEXX Laboratories Inc.
- ISIN: US45168D1046
- Ticker: NASDAQ: IDXX
- Trading venue: Nasdaq
- Market capitalization: around $45 billion to $50 billion (as of mid 2026)
- Sector / Industry: Healthcare diagnostics and veterinary technology
- Index membership: major US equity benchmarks for healthcare and diagnostics
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
